Stifel Nicolaus initiated coverage on Baxter International BAX with a Hold rating.
Stifel Nicolaus said, "We view BAX as one of the better positioned companies in our universe of large-cap Medical Technology & Supply stocks in its ability to deliver consistent sales and earnings growth over the next two-three years. Still, at current share price levels, even with now lowered concerns regarding competition from Biogen Idec's (BIIB ($141.24) Buy, covered by our colleague Joel Sendek) longer acting rFVIII program, we believe that in order for the stock to move above the $70 level, we would require greater revenue upside beyond our currently modeled assumptions."
Baxter International closed at $66.02 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in